Sunday July 5, 2020

Royalty chasing Elan approval

Newsmaker: Pablo Legorreta.

15th June, 2013
Pablo Legorreta, chief executive, Royalty Pharma.

Royalty Pharma chief executive Pablo Legorreta is telling Elan's shareholders to keep their options open - asking them to align with his company's offer for the Dublin-based drug firm.

Legorreta has been chasing approval from investors ever since launching a hostile takeover bid in the wake of Elan's decision to sell its stake in the multiple sclerosis drug Tysabri to Biogen as part of a restructuring of the business.

Elan has been furious in its...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 6 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago